Serious haematological toxicity during and after ipilimumab treatment: A case series

Journal of Medical Case Reports

Volumn 8, Issue 1, 2014, Pages

  Simeone, Ester ^a   Grimaldi, Antonio Maria ^a   Esposito, Assunta ^a   Curvietto, Marcello ^a   Palla, Marco ^a   Paone, Miriam ^a   Mozzillo, Nicola ^a   Ascierto, Paolo Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anaemia; CTLA 4 blockade; Immune related adverse events; Immunotherapy; Ipilimumab; Leukopenia; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; FOTEMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISONE; TEMOZOLOMIDE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALGORITHM; ANEMIA; ARTICLE; AUTOIMMUNITY; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CAUCASIAN; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ERYTHROCYTE; EYE TUMOR; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL NEUROIMAGING; HUMAN; KIDNEY TUMOR; LEUKOPENIA; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PRURITUS; THROMBOCYTE COUNT; TREATMENT OUTCOME; WHOLE BODY CT; CHEMICALLY INDUCED; NEOPLASMS; NEUTROPENIA; SEVERITY OF ILLNESS INDEX;

AGED; ANEMIA; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SEVERITY OF ILLNESS INDEX;

EID: 84904177881     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-8-240     Document Type: Article

References (13)

1. Improved survival with ipilimumab in patients with metastatic melanoma. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ, N Engl J Med 2010 363 711 723 10.1056/NEJMoa1003466 20525992
2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD, N Engl J Med 2011 364 2517 2526 10.1056/NEJMoa1104621 21639810
3. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. Ibrahim R, Berman D, de Pril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A, J Clin Oncol 2011 29 Suppl Abstract 8583
4. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, et al. PLoS One 2013 8 53745 10.1371/journal.pone.0053745 23341990
5. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF, Cancer Immunol Immunother 2009 58 1351 1353 10.1007/s00262-008-0627-x 19052742
6. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, Arellano ML, J Immunother 2009 32 322 324 10.1097/CJI.0b013e31819aa40b 19242368
7. Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Wei G, Nwakuche U, Cadavid G, Ajaz A, Seiter K, Liu D, Exp Hematol Oncol 2012 1 1 3 10.1186/2162-3619-1-3 23210632
8. Efficacy, safety, and correlation with mutation status in metastatic melanoma patients. Queirolo P, Spagnolo F, Altomonte M, Chiarion-Sileni V, Pigozzo J, Del Vecchio M, Di Guardo L, Ridolfi R, Scoppola A, Ferrucci PF, Ferraresi V, Bernengo MG, Guida M, Marconcini R, Mandalà M, Parmiani G, Rinaldi G, Aglietta M, Simeone E, Ascierto PA, Italian cohort of ipilimumab expanded access programme (EAP), J Clin Oncol 2013 31 Suppl Abstract 9070
9. Management of immune-related adverse events and kinetics of response with ipilimumab. Weber JS, Kähler KC, Hauschild A, J Clin Oncol 2012 30 2691 2697 10.1200/JCO.2012.41.6750 22614989
10. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A, J Clin Oncol 2013 31 616 622 10.1200/JCO.2012.44.6112 23295794
11. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, MDX010-20 Investigators, Cancer 2013 119 1675 1682 10.1002/cncr.27969 23400564
12. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10mg/kg ipilimumab in three phase II clinical trials. Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, de Pril V, Ibrahim R, Hoos A, O'Day S, J Clin Oncol 2009 27 Suppl Abstract 9034
13. Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). Di Giacomo AM, Grimaldi AM, Ascierto PA, Queirolo P, Del Vecchio M, Ridolfi R, De Rosa F, De Galitiis F, Testori A, Cognetti F, Bernengo MG, Savoia P, Guida M, Strippoli S, Galli L, Mandala M, Parmiani G, Rinaldi G, Aglietta M, Chiarion-Sileni V, J Clin Oncol 2013 31 Suppl Abstract 9065